New FDA approvals, pivotal clinical trial results, and innovative treatment strategies emerged in the field of genitourinary cancers in 2024. Here are 10 of the top developments from the field this ...
Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...
On January 8, 2025, the Department of Veterans Affairs (VA) announced it was adding eight (8) new presumptives for disabled veterans. These new presumptives are: acute and chronic ...